Seminar Paper in the Module "Scientific Work"

Abstract

This research examines the structural dynamics shaping China's biotechnology industry and investigates how Hengrui Medicine---a leading domestic innovator---has navigated evolving macro-environmental conditions and strategic growth imperatives. Drawing on the PEST framework, the study systematically analyzes political, economic, social, and technological forces that have collectively redefined regulatory expectations, funding landscapes, talent mobility, and R&D infrastructure over the past decade. Concurrently, the Ansoff Matrix serves as the core strategic lens to map Hengrui Medicine's deliberate progression across market penetration, product development, market development, and diversification pathways. Empirical analysis reveals a tightly coupled alignment between national policy acceleration---such as the 2015 Drug Review Reform and subsequent innovation incentives---and the firm's internal capability-building in oncology-focused drug discovery, clinical trial execution, and international regulatory engagement. The findings demonstrate that Hengrui's sustained growth is not attributable to isolated tactical decisions but to an iterative, feedback-driven strategy wherein external environmental scanning continuously informs internal resource allocation and portfolio prioritization. Importantly, the study identifies emerging tensions---including intensifying domestic competition, global IP scrutiny, and shifting reimbursement frameworks---that challenge the scalability of prior growth logic. By integrating macro-level institutional analysis with micro-level corporate strategy, this work contributes a contextualized, process-oriented understanding of innovation-led industrial upgrading in a state-influenced emerging economy.